Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
27.38
+0.11 (0.40%)
At close: May 15, 2026, 4:00 PM EDT
27.15
-0.23 (-0.84%)
After-hours: May 15, 2026, 5:24 PM EDT

Mineralys Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
5338.623.8214.35.232.42
Research & Development
118.5132.01168.5870.3626.2516.31
Total Operating Expenses
171.5170.6192.484.6631.4818.73
Operating Income
-171.5-170.6-192.4-84.66-31.48-18.73
Interest Income
19.7115.9514.5912.761.68-0.03
Other Non-Operating Income (Expense)
0.01-0.0100-0.66
Total Non-Operating Income (Expense)
19.7215.9514.5912.761.68-0.68
Pretax Income
-151.78-154.65-177.81-71.9-29.8-19.41
Net Income
-151.78-154.65-177.81-71.9-29.8-19.41
Net Income to Common
-151.78-154.65-177.81-71.9-29.8-19.41
Shares Outstanding (Basic)
7568493655
Shares Outstanding (Diluted)
7568493655
Shares Change (YoY)
48.02%39.38%34.13%600.33%3.67%-7.90%
EPS (Basic)
-2.05-2.29-3.66-1.99-5.77-3.89
EPS (Diluted)
-2.05-2.29-3.66-1.99-5.77-3.89
Shares Outstanding
82.4681.5449.8241.136.425.44
Free Cash Flow
-136.42-142.43-166.41-81.17-29.22-14.56
Free Cash Flow Per Share
-1.82-2.11-3.43-2.24-5.65-2.92
EBITDA
-171.45-170.55-192.36-84.66-31.48-18.73
EBIT
-171.5-170.6-192.4-84.66-31.48-18.73
Updated May 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q